RU2010129549A - Двухвалентные биспецифические антитела - Google Patents
Двухвалентные биспецифические антитела Download PDFInfo
- Publication number
- RU2010129549A RU2010129549A RU2010129549/10A RU2010129549A RU2010129549A RU 2010129549 A RU2010129549 A RU 2010129549A RU 2010129549/10 A RU2010129549/10 A RU 2010129549/10A RU 2010129549 A RU2010129549 A RU 2010129549A RU 2010129549 A RU2010129549 A RU 2010129549A
- Authority
- RU
- Russia
- Prior art keywords
- domain
- heavy chain
- antibody
- interface
- chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
1. Двухвалентное биспецифическое антитело, содержащее: ! а) легкую цепь и тяжелую цепь антитела, специфически связывающегося с первым антигеном; и ! б) легкую цепь и тяжелую цепь антитела, специфически связывающегося со вторым антигеном, в котором вариабельные домены VL и VH заменены друг на друга. ! 2. Антитело по п.1, отличающееся тем, что ! СН3-домен одной тяжелой цепи и СН3-домен другой тяжелой цепи каждый соприкасается друг с другом на поверхности раздела, которая представляет собой исходную поверхность раздела между СН3-доменами антитела; при этом поверхность раздела изменена для активации формирования двухвалентного биспецифического антитела, где изменение отличается тем, что: ! а) изменен СН3-домен одной тяжелой цепи ! так, что на исходной поверхности раздела СН3-домена одной тяжелой цепи, которая соприкасается с исходной поверхностью раздела СН3-домена второй тяжелой цепи в двухвалентном биспецифическом антителе, аминокислотный остаток заменен на аминокислотный остаток, который имеет большую по объему боковую цепь, что приводит к созданию выпуклости на поверхности раздела СН3-домена одной тяжелой цепи, которая может помещаться в полость на поверхности раздела СН3-домена другой тяжелой цепи, ! и ! б) изменен СН3-домен другой тяжелой цепи ! так, что на исходной поверхности раздела второго СН3-домена, которая соприкасается с исходной поверхностью раздела первого СН3-домена в двухвалентном биспецифическом антителе, аминокислотный остаток заменен на аминокислотный остаток, который имеет меньшую по объему боковую цепь, что приводит к созданию полости на поверхности раздела второго СН3-домена, в которую может по�
Claims (10)
1. Двухвалентное биспецифическое антитело, содержащее:
а) легкую цепь и тяжелую цепь антитела, специфически связывающегося с первым антигеном; и
б) легкую цепь и тяжелую цепь антитела, специфически связывающегося со вторым антигеном, в котором вариабельные домены VL и VH заменены друг на друга.
2. Антитело по п.1, отличающееся тем, что
СН3-домен одной тяжелой цепи и СН3-домен другой тяжелой цепи каждый соприкасается друг с другом на поверхности раздела, которая представляет собой исходную поверхность раздела между СН3-доменами антитела; при этом поверхность раздела изменена для активации формирования двухвалентного биспецифического антитела, где изменение отличается тем, что:
а) изменен СН3-домен одной тяжелой цепи
так, что на исходной поверхности раздела СН3-домена одной тяжелой цепи, которая соприкасается с исходной поверхностью раздела СН3-домена второй тяжелой цепи в двухвалентном биспецифическом антителе, аминокислотный остаток заменен на аминокислотный остаток, который имеет большую по объему боковую цепь, что приводит к созданию выпуклости на поверхности раздела СН3-домена одной тяжелой цепи, которая может помещаться в полость на поверхности раздела СН3-домена другой тяжелой цепи,
и
б) изменен СН3-домен другой тяжелой цепи
так, что на исходной поверхности раздела второго СН3-домена, которая соприкасается с исходной поверхностью раздела первого СН3-домена в двухвалентном биспецифическом антителе, аминокислотный остаток заменен на аминокислотный остаток, который имеет меньшую по объему боковую цепь, что приводит к созданию полости на поверхности раздела второго СН3-домена, в которую может помещаться выпуклость на поверхности раздела первого СН3-домена.
3. Антитело по п.2, отличающееся тем, что
указанный аминокислотный остаток, который имеет большую по объему боковую цепь, выбран из группы, включающей аргинин (R), фенилаланин (F), тирозин (Y), триптофан (W).
4. Антитело по п.2 или 3, отличающееся тем, что
указанный аминокислотный остаток, который имеет меньшую по объему боковую цепь, выбран из группы, включающей аланин (А), серин (S), треонин (Т), валин (V).
5. Антитело по п.2 или 3, отличающееся тем, что
оба СН3-домена дополнительно изменены путем интродукции цистеина (С) в качестве аминокислоты в соответствующие положения каждого СН3-домена.
6. Антитело по п.1, отличающееся тем, что
один из СН3-доменов константной области тяжелой цепи обеих тяжелых цепей заменен на СН1-домен константной области тяжелой цепи; а другой СН3-домен константной области тяжелой цепи заменен на CL-домен константной области легкой цепи.
7. Способ получения двухвалентного биспецифического антитела по п.1, заключающийся в том, что
а) трансформируют клетку-хозяина
- векторами, которые содержат молекулы нуклеиновых кислот, кодирующие легкую цепь и тяжелую цепь антитела, специфически связывающегося с первым антигеном,
- векторами, которые содержат молекулы нуклеиновых кислот, кодирующие легкую цепь и тяжелую цепь антитела, специфически связывающегося со вторым антигеном, в котором вариабельные домены VL и VH заменены друг на друга;
б) культивируют клетку-хозяина в условиях, которые позволяют синтезировать указанную молекулу антитела; и
в) выделяют молекулу антитела из культуры.
8. Клетка-хозяин, содержащая:
- векторы, которые содержат молекулы нуклеиновых кислот, кодирующие легкую цепь и тяжелую цепь антитела, специфически связывающегося с первым антигеном,
- векторы, которые содержат молекулы нуклеиновых кислот, кодирующие легкую цепь и тяжелую цепь антитела, специфически связывающегося со вторым антигеном, в котором вариабельные домены VL и VH заменены друг на друга.
9. Композиция, предпочтительно фармацевтическая или диагностическая композиция двухвалентного биспецифического антитела по пп.1-6.
10. Фармацевтическая композиция, содержащая двухвалентное биспецифическое антитело по пп.1-6 и по меньшей мере один фармацевтически приемлемый эксципиент.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07024864 | 2007-12-21 | ||
| EP07024864.6 | 2007-12-21 | ||
| PCT/EP2008/010703 WO2009080252A1 (en) | 2007-12-21 | 2008-12-16 | Bivalent, bispecific antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010129549A true RU2010129549A (ru) | 2012-01-27 |
| RU2587616C2 RU2587616C2 (ru) | 2016-06-20 |
Family
ID=39093026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010129549/10A RU2587616C2 (ru) | 2007-12-21 | 2008-12-16 | Двухвалентные биспецифические антитела |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US20090162359A1 (ru) |
| EP (1) | EP2225279B1 (ru) |
| JP (1) | JP5281097B2 (ru) |
| KR (1) | KR101249607B1 (ru) |
| CN (1) | CN101903404B (ru) |
| AR (1) | AR071547A1 (ru) |
| AU (1) | AU2008340693A1 (ru) |
| BR (1) | BRPI0821791B1 (ru) |
| CA (1) | CA2709023C (ru) |
| CL (1) | CL2008003781A1 (ru) |
| CO (1) | CO6280542A2 (ru) |
| CR (1) | CR11460A (ru) |
| EC (1) | ECSP10010270A (ru) |
| ES (1) | ES2469791T3 (ru) |
| IL (1) | IL206161A0 (ru) |
| MA (1) | MA31904B1 (ru) |
| MX (1) | MX2010006396A (ru) |
| NZ (1) | NZ585627A (ru) |
| PE (1) | PE20091172A1 (ru) |
| RU (1) | RU2587616C2 (ru) |
| TW (1) | TWI359027B (ru) |
| WO (1) | WO2009080252A1 (ru) |
Families Citing this family (445)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| CN101537180B (zh) | 2002-07-18 | 2016-02-10 | 莫鲁斯有限公司 | 抗体混合物的重组生产 |
| EP3345616A1 (en) | 2006-03-31 | 2018-07-11 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) * | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| CA2756244A1 (en) * | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
| SG175078A1 (en) | 2009-04-07 | 2011-11-28 | Roche Glycart Ag | Bispecific anti-erbb-1/anti-c-met antibodies |
| MX2011010166A (es) | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-3/anti-c-met. |
| MX2011010168A (es) | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos, trivalentes. |
| TW201100543A (en) * | 2009-05-27 | 2011-01-01 | Hoffmann La Roche | Tri-or tetraspecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| RU2015153109A (ru) | 2009-09-16 | 2019-01-15 | Дженентек, Инк. | Содержащие суперспираль и/или привязку белковые комплексы и их применения |
| KR101762467B1 (ko) | 2010-01-29 | 2017-07-27 | 도레이 카부시키가이샤 | 폴리락트산계 수지 시트 |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| BR112012033162A2 (pt) | 2010-07-19 | 2016-10-25 | Hoffmann La Roche | método de identificação de pacientes, método de previsão da capacidade de reação de pacientes, método de determinação da probabilidade de um paciente com câncer exibir benefícios de terapia anticâncer, método de otimização da eficácia terapêutica, método de tratamento de câncer, kit e conjunto de compostos |
| EP2596359A1 (en) | 2010-07-19 | 2013-05-29 | F.Hoffmann-La Roche Ag | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
| BR112013002532A2 (pt) | 2010-08-05 | 2016-05-31 | Hoffmann La Roche | proteína de fusão de citocina anti-viral do anticorpo anti-mhc |
| JP5758004B2 (ja) | 2010-08-24 | 2015-08-05 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体 |
| AR084053A1 (es) | 2010-11-30 | 2013-04-17 | Chugai Pharmaceutical Co Ltd | Agente terapeutico que induce citotoxicidad |
| SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| KR101572338B1 (ko) | 2011-02-28 | 2015-11-26 | 에프. 호프만-라 로슈 아게 | 1가 항원 결합 단백질 |
| KR101638224B1 (ko) | 2011-02-28 | 2016-07-08 | 에프. 호프만-라 로슈 아게 | 항원 결합 단백질 |
| TWI671315B (zh) * | 2011-03-28 | 2019-09-11 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| EP2699600A1 (en) | 2011-04-20 | 2014-02-26 | Roche Glycart AG | Method and constructs for the ph dependent passage of the blood-brain-barrier |
| EP2714738B1 (en) * | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| CA2837914A1 (en) | 2011-06-15 | 2012-12-20 | F. Hoffmann-La Roche Ag | Anti-human epo receptor antibodies and methods of use |
| WO2012177775A1 (en) * | 2011-06-20 | 2012-12-27 | Akrivis Technologies, Llc | Reagents and methods for bispecific antibody-based binding of target molecules |
| CN103649125A (zh) | 2011-06-22 | 2014-03-19 | 霍夫曼-拉罗奇有限公司 | 利用包含mhc i类的复合物通过循环中的病毒特异性细胞毒性t细胞清除靶细胞 |
| US20130058937A1 (en) * | 2011-08-23 | 2013-03-07 | Johannes Auer | Bispecific antigen binding molecules |
| KR101681818B1 (ko) | 2011-08-23 | 2016-12-01 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
| EP2758435A1 (en) | 2011-09-23 | 2014-07-30 | Roche Glycart AG | Bispecific anti-egfr/anti igf-1r antibodies |
| CN109111524B (zh) | 2011-10-31 | 2022-10-28 | 中外制药株式会社 | 控制了重链与轻链的缔合的抗原结合分子 |
| CA2853917A1 (en) | 2011-12-19 | 2013-06-27 | F. Hoffmann-La Roche Ag | Method for the detection of free binding partner of a multispecific binder |
| CA3125875A1 (en) | 2011-12-22 | 2013-06-27 | F.Hoffmann-La Roche Ag | Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides |
| CA2854249C (en) | 2011-12-22 | 2022-05-03 | F. Hoffmann-La Roche Ag | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
| EP2794662A1 (en) | 2011-12-22 | 2014-10-29 | F.Hoffmann-La Roche Ag | Full length antibody display system for eukaryotic cells and its use |
| CN104105966B (zh) | 2012-02-01 | 2016-10-26 | 弗·哈夫曼-拉罗切有限公司 | 用于检测多特异性结合物的结合搭档的方法 |
| EP2809682B1 (en) | 2012-02-03 | 2020-04-08 | F.Hoffmann-La Roche Ag | Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine |
| MX2014009565A (es) | 2012-02-10 | 2014-11-10 | Genentech Inc | Anticuerpos monocatenarios y otros heteromultimeros. |
| US20150018241A1 (en) | 2012-02-15 | 2015-01-15 | Hoffmann-La Roche Inc. | Fc-receptor based affinity chromatography |
| BR112014024903A2 (pt) | 2012-04-05 | 2017-07-11 | Hoffmann La Roche | anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos |
| SG10201913376XA (en) | 2012-04-20 | 2020-02-27 | Merus Nv | Methods and means for the production of ig-like molecules |
| US9062120B2 (en) | 2012-05-02 | 2015-06-23 | Janssen Biotech, Inc. | Binding proteins having tethered light chains |
| MX2014014162A (es) * | 2012-05-24 | 2015-02-04 | Hoffmann La Roche | Anticuerpos multiespecificos. |
| MX2014014804A (es) | 2012-06-27 | 2015-02-12 | Hoffmann La Roche | Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo. |
| JP6203838B2 (ja) | 2012-06-27 | 2017-09-27 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 少なくとも２つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用 |
| SI2869848T1 (sl) | 2012-07-04 | 2017-01-31 | F. Hoffmann-La Roche Ag | Kovalentno vezani konjugati antigen-protitelo |
| RU2630296C2 (ru) | 2012-07-04 | 2017-09-06 | Ф. Хоффманн-Ля Рош Аг | Антитела к биотину и способы их применения |
| WO2014006118A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Anti-theophylline antibodies and methods of use |
| MA37794B1 (fr) | 2012-07-13 | 2017-07-31 | Roche Glycart Ag | Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le cadre du traitement de pathologies vasculaires oculaires |
| EP2872893B1 (en) | 2012-07-13 | 2017-03-29 | F. Hoffmann-La Roche AG | Method for the detection of a multispecific antibody |
| EP2895496B1 (en) | 2012-09-14 | 2017-06-07 | F. Hoffmann-La Roche AG | Method for the production and selection of molecules comprising at least two different entities and uses thereof |
| ES2692951T3 (es) | 2012-09-27 | 2018-12-05 | Merus N.V. | Anticuerpos IgG biespecíficos como acopladores de células T |
| BR112015007120A2 (pt) | 2012-10-08 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo |
| EP2917243B1 (en) | 2012-11-08 | 2018-03-14 | F.Hoffmann-La Roche Ag | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
| TW202423993A (zh) * | 2012-11-14 | 2024-06-16 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
| WO2014122143A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | Method for the selection of antibodies against bcma |
| EP2762497A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
| JP6499087B2 (ja) | 2013-02-26 | 2019-04-10 | ロシュ グリクアート アーゲー | 二重特異性ｔ細胞活性化抗原結合分子 |
| JP2016512421A (ja) * | 2013-02-26 | 2016-04-28 | ロシュ グリクアート アーゲー | 二重特異性ｔ細胞活性化抗原結合分子 |
| CA2891493C (en) | 2013-02-26 | 2022-03-15 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| US10150800B2 (en) | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| EP3878866A1 (en) | 2013-04-29 | 2021-09-15 | F. Hoffmann-La Roche AG | Fc-receptor binding modified asymmetric antibodies and methods of use |
| EP3327034A1 (en) | 2013-04-29 | 2018-05-30 | F. Hoffmann-La Roche AG | Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases |
| SG11201508911PA (en) | 2013-04-29 | 2015-11-27 | Hoffmann La Roche | Human fcrn-binding modified antibodies and methods of use |
| WO2015025054A1 (en) | 2013-08-22 | 2015-02-26 | Medizinische Universität Wien | Dye-specific antibodies for prestained molecular weight markers and methods producing the same |
| AU2014325063B2 (en) | 2013-09-27 | 2019-10-31 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
| CN105612182B (zh) | 2013-10-11 | 2019-12-10 | 豪夫迈·罗氏有限公司 | 多特异性结构域交换共有可变轻链抗体 |
| CN105722857B (zh) | 2013-11-21 | 2023-03-24 | 豪夫迈·罗氏有限公司 | 抗-α-突触核蛋白抗体及使用方法 |
| CN112062853B (zh) | 2013-12-20 | 2024-01-09 | 豪夫迈·罗氏有限公司 | 双特异性her2抗体及使用方法 |
| CA2932958A1 (en) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Humanized anti-tau(ps422) antibodies and methods of use |
| EP3089759B1 (en) | 2014-01-03 | 2018-12-05 | F. Hoffmann-La Roche AG | Covalently linked polypeptide toxin-antibody conjugates |
| KR102278979B1 (ko) | 2014-01-03 | 2021-07-19 | 에프. 호프만-라 로슈 아게 | 공유적으로 연결된 헬리카-항-헬리카 항체 접합체 및 그의 용도 |
| PL3089996T3 (pl) | 2014-01-03 | 2021-12-13 | F. Hoffmann-La Roche Ag | Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg |
| WO2015101588A1 (en) | 2014-01-06 | 2015-07-09 | F. Hoffmann-La Roche Ag | Monovalent blood brain barrier shuttle modules |
| JP6786392B2 (ja) | 2014-01-15 | 2020-11-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ＦｃＲｎ結合特性が改変され、プロテインＡ結合特性が保持されているＦｃ領域変異体 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| CA2941077A1 (en) | 2014-02-28 | 2015-09-03 | Merus N.V. | Antibody that binds erbb-2 and erbb-3 |
| US10844127B2 (en) | 2014-02-28 | 2020-11-24 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
| WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| KR102376287B1 (ko) | 2014-04-02 | 2022-03-17 | 에프. 호프만-라 로슈 아게 | 다중특이적 항체 경쇄 잘못짝짓기의 검출 방법 |
| ES2900898T3 (es) | 2014-04-07 | 2022-03-18 | Chugai Pharmaceutical Co Ltd | Anticuerpos biespecíficos inmunoactivadores |
| KR102603417B1 (ko) | 2014-05-06 | 2023-11-20 | 제넨테크, 인크. | 포유동물 세포를 사용한 이종다량체 단백질의 생산 |
| AU2015260230A1 (en) | 2014-05-13 | 2016-11-17 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
| AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| CA2947504A1 (en) | 2014-06-26 | 2015-12-30 | F. Hoffmann-La Roche Ag | Anti-brdu antibodies and methods of use |
| TW201623329A (zh) | 2014-06-30 | 2016-07-01 | 亞佛瑞司股份有限公司 | 針對骨調素截斷變異體的疫苗及單株抗體暨其用途 |
| MX2016017393A (es) | 2014-07-01 | 2017-09-05 | Pfizer | Diacuerpos heterodimericos biespecificos y sus usos. |
| EP3166966A1 (en) | 2014-07-10 | 2017-05-17 | Affiris AG | Substances and methods for the use in prevention and/or treatment in huntington's disease |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| AU2015292744C1 (en) | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| AU2015292755B2 (en) | 2014-07-21 | 2020-11-12 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
| ES2781175T3 (es) | 2014-07-31 | 2020-08-31 | Novartis Ag | Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico |
| EP2982692A1 (en) * | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| ES2979976T3 (es) | 2014-08-04 | 2024-09-27 | Hoffmann La Roche | Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas |
| WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
| TWI719946B (zh) | 2014-08-19 | 2021-03-01 | 瑞士商諾華公司 | 使用ｃｄ１２３嵌合抗原受體治療癌症 |
| KR102590396B1 (ko) | 2014-09-17 | 2023-10-19 | 노파르티스 아게 | 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화 |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| US11952421B2 (en) | 2014-10-09 | 2024-04-09 | Bristol-Myers Squibb Company | Bispecific antibodies against CD3EPSILON and ROR1 |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| AR102521A1 (es) | 2014-11-06 | 2017-03-08 | Hoffmann La Roche | Variantes de región fc con unión de fcrn modificada y métodos de utilización |
| KR20170076697A (ko) | 2014-11-06 | 2017-07-04 | 에프. 호프만-라 로슈 아게 | 개질된 FCRN-결합 특성 및 단백질 A-결합 특성을 가진 Fc-영역 변이체 |
| KR20170082594A (ko) | 2014-11-10 | 2017-07-14 | 에프. 호프만-라 로슈 아게 | 항-ang2 항체 및 사용 방법 |
| CA2963175A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use in ophthalmology |
| KR20170087486A (ko) | 2014-11-20 | 2017-07-28 | 에프. 호프만-라 로슈 아게 | 일반 경쇄 및 이의 사용 방법 |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| MX2017006610A (es) | 2014-11-20 | 2017-09-29 | Hoffmann La Roche | Terapia combinada de moleculas de union a antigeno biespecificas activadoras de celulas t y antagonistas de union de eje de pd-1. |
| WO2016087514A1 (en) | 2014-12-02 | 2016-06-09 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies |
| PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
| WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
| EP3234598B1 (en) | 2014-12-18 | 2019-11-06 | F.Hoffmann-La Roche Ag | Assay and method for determining cdc eliciting antibodies |
| DK3280729T3 (da) | 2015-04-08 | 2022-07-25 | Novartis Ag | Cd20-behandlinger, cd22-behandlinger og kombinationsbehandlinger med en cd19-kimær antigenreceptor (car)-udtrykkende celle |
| WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| MX2017013482A (es) | 2015-04-24 | 2018-03-01 | Genentech Inc | Proteinas multiespecificas de union al antigeno. |
| MY180297A (en) * | 2015-06-24 | 2020-11-27 | Hoffmann La Roche | Anti-transferrin receptor antibodies with tailored affinity |
| CN113929779A (zh) | 2015-06-24 | 2022-01-14 | 豪夫迈·罗氏有限公司 | 人源化的抗-Tau(pS422)抗体和使用方法 |
| KR20180033523A (ko) | 2015-07-10 | 2018-04-03 | 젠맵 에이/에스 | 암 치료를 위한 axl-특이적 항체-약물 접합체 |
| HUE042039T2 (hu) | 2015-07-10 | 2019-06-28 | Merus Nv | Humán CD3 kötõ antitest |
| EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| PT3317301T (pt) | 2015-07-29 | 2021-07-09 | Novartis Ag | Terapias de associação compreendendo moléculas de anticorpo contra lag-3 |
| CN114272371A (zh) | 2015-07-29 | 2022-04-05 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| AU2016302881B2 (en) | 2015-08-03 | 2022-09-15 | Bristol-Myers Squibb Company | Monoclonal antibodies against BCMA |
| BR112018006251A2 (pt) | 2015-09-30 | 2018-10-16 | Janssen Biotech Inc | anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| KR20180053674A (ko) | 2015-10-02 | 2018-05-23 | 에프. 호프만-라 로슈 아게 | 공자극 tnf 수용체에 특이적인 이중특이성 항체 |
| EP3356821B1 (en) | 2015-10-02 | 2019-10-23 | H. Hoffnabb-La Roche Ag | Cellular based fret assay for the determination of simultaneous binding |
| RU2746409C1 (ru) | 2015-10-02 | 2021-04-13 | Ф. Хоффманн-Ля Рош Аг | Антитела к pd1 и способы их применения |
| CN107949574A (zh) * | 2015-10-02 | 2018-04-20 | 豪夫迈·罗氏有限公司 | 双特异性t细胞活化性抗原结合分子 |
| EP3150636A1 (en) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
| EP3150637A1 (en) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Multispecific antibodies |
| WO2017055392A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules |
| AR106201A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | Moléculas biespecíficas de unión a antígeno activadoras de células t |
| WO2017055385A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xgd2 bispecific t cell activating antigen binding molecules |
| RU2753390C1 (ru) | 2015-10-02 | 2021-08-13 | Ф. Хоффманн-Ля Рош Аг | Биспецифические антитела к человеческому cd20/человеческому рецептору трансферрина и способы их применения |
| US20180282410A1 (en) | 2015-10-02 | 2018-10-04 | Hoffmann-La Roche Inc. | Anti-cd3xrob04 bispecific t cell activating antigen binding molecules |
| WO2017055393A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| CR20180161A (es) | 2015-10-02 | 2018-05-25 | Hoffmann La Roche | Anticuerpos biespecíficos para pd1 y tim3 |
| CN108026177B (zh) | 2015-10-02 | 2021-11-26 | 豪夫迈·罗氏有限公司 | 双特异性抗cd19xcd3 t细胞活化性抗原结合分子 |
| US20170096485A1 (en) | 2015-10-02 | 2017-04-06 | Hoffmann-La Roche Inc. | Bispecific t cell activating antigen binding molecules |
| MX2018004157A (es) | 2015-10-07 | 2019-04-01 | F Hoffmann La Roche Ag | Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador. |
| ES2865482T3 (es) | 2015-10-23 | 2021-10-15 | Merus Nv | Moléculas de unión que inhiben el crecimiento del cáncer |
| EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
| CN114891102A (zh) | 2015-10-29 | 2022-08-12 | 豪夫迈·罗氏有限公司 | 抗变体Fc区抗体及使用方法 |
| CN116333125A (zh) | 2015-10-30 | 2023-06-27 | 银河生物技术有限责任公司 | 结合死亡受体4和死亡受体5的抗体 |
| CR20180234A (es) | 2015-11-03 | 2018-09-11 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| WO2017086419A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
| EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
| JP7325186B2 (ja) | 2015-12-09 | 2023-08-14 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗薬物抗体の形成を減少させるためのｉｉ型抗ｃｄ２０抗体 |
| AU2016369537B2 (en) | 2015-12-17 | 2024-03-14 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
| AU2016369623A1 (en) | 2015-12-17 | 2018-06-28 | Novartis Ag | Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof |
| US11447575B2 (en) | 2015-12-18 | 2022-09-20 | Biogen Ma Inc. | Bispecific antibody platform |
| US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
| AR107303A1 (es) | 2016-01-08 | 2018-04-18 | Hoffmann La Roche | Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit |
| ES2847155T3 (es) | 2016-01-21 | 2021-08-02 | Novartis Ag | Moléculas multiespecíficas que fijan como objetivo CLL-1 |
| CA3016287A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| TW201735947A (zh) | 2016-03-14 | 2017-10-16 | Chugai Pharmaceutical Co Ltd | 用於癌之治療的細胞傷害誘導治療劑 |
| PL3433280T3 (pl) | 2016-03-22 | 2023-07-31 | F. Hoffmann-La Roche Ag | Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy |
| WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
| CA3021027A1 (en) | 2016-04-15 | 2017-10-19 | Novartis Ag | Compositions and methods for selective expression of chimeric antigen receptors |
| EP3452502B1 (en) | 2016-05-02 | 2021-03-03 | H. Hoffnabb-La Roche Ag | The contorsbody - a single chain target binder |
| CN109312408B (zh) | 2016-05-17 | 2022-12-23 | 豪夫迈·罗氏有限公司 | 用于诊断和供免疫疗法中使用的基质基因签名 |
| EP3464375A2 (en) | 2016-06-02 | 2019-04-10 | Novartis AG | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
| AU2018276419A1 (en) | 2016-06-02 | 2019-10-17 | F. Hoffmann-La Roche Ag | Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| WO2017218977A2 (en) | 2016-06-17 | 2017-12-21 | Genentech, Inc. | Purification of multispecific antibodies |
| US20190233534A1 (en) | 2016-07-14 | 2019-08-01 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
| AU2017295886C1 (en) | 2016-07-15 | 2024-05-16 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| CN110214150A (zh) | 2016-07-28 | 2019-09-06 | 诺华股份有限公司 | 嵌合抗原受体和pd-1抑制剂的组合疗法 |
| KR20190036551A (ko) | 2016-08-01 | 2019-04-04 | 노파르티스 아게 | Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료 |
| EP3497126A4 (en) | 2016-08-12 | 2020-04-08 | Janssen Biotech, Inc. | ANTIBODIES OF FC MODIFIED ANTI-TNFR SUPERFAMILY HAVING IMPROVED AGONIST ACTIVITY AND METHODS OF USE THEREOF |
| JP7178342B2 (ja) | 2016-08-12 | 2022-11-25 | ヤンセン バイオテツク，インコーポレーテツド | アゴニズム及びエフェクター機能が増強した改変抗体、及び他のＦｃドメイン含有分子 |
| EP3515932B1 (en) | 2016-09-19 | 2023-11-22 | F. Hoffmann-La Roche AG | Complement factor based affinity chromatography |
| EP3519820B1 (en) | 2016-09-30 | 2020-12-09 | H. Hoffnabb-La Roche Ag | Spr-based dual-binding assay for the functional analysis of multispecific molecules |
| JP7022123B2 (ja) | 2016-09-30 | 2022-02-17 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｃｄ３に対する二重特異性抗体 |
| BR112019006781A2 (pt) | 2016-10-07 | 2019-07-30 | Novartis Ag | receptores de antígeno quiméricos para o tratamento de câncer |
| AU2017353427A1 (en) | 2016-11-02 | 2019-05-16 | Bristol-Myers Squibb Company | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| TN2019000164A1 (en) | 2016-11-23 | 2020-10-05 | Bioverativ Therapeutics Inc | Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x |
| KR102669762B1 (ko) | 2016-12-19 | 2024-05-30 | 에프. 호프만-라 로슈 아게 | 표적화된 4-1bb(cd137) 작용물질과의 병용 요법 |
| CA3039446A1 (en) | 2016-12-20 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists |
| MX2019006123A (es) | 2016-12-21 | 2019-08-12 | Hoffmann La Roche | Metodo para glicomanipulacion in vitro de anticuerpos. |
| CN110088291A (zh) | 2016-12-21 | 2019-08-02 | 豪夫迈·罗氏有限公司 | 用于体外糖工程化抗体的方法 |
| WO2018114878A1 (en) | 2016-12-21 | 2018-06-28 | F. Hoffmann-La Roche Ag | Re-use of enzymes in in vitro glycoengineering of antibodies |
| JP7122311B2 (ja) | 2017-01-03 | 2022-08-19 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗４－１ｂｂクローン２０ｈ４．９を含む二重特異性抗原結合分子 |
| ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
| WO2018160731A1 (en) | 2017-02-28 | 2018-09-07 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
| CA3052357A1 (en) | 2017-03-10 | 2018-09-13 | F. Hoffmann-La Roche Ag | Method for producing multispecific antibodies |
| WO2018178055A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
| EP3601346A1 (en) | 2017-03-29 | 2020-02-05 | H. Hoffnabb-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
| AU2018246873B2 (en) | 2017-03-31 | 2021-05-06 | Merus N.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene |
| MX2019011520A (es) | 2017-03-31 | 2020-08-03 | Genmab Holding B V | Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos. |
| SG11201909218RA (en) | 2017-04-03 | 2019-11-28 | Hoffmann La Roche | Antibodies binding to steap-1 |
| WO2018184965A1 (en) | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody |
| MX2019011907A (es) | 2017-04-04 | 2020-01-09 | Hoffmann La Roche | Nuevas moleculas de union a antigeno biespecificas capaces de unirse especificamente a cd40 y a fap. |
| UA128451C2 (uk) | 2017-04-05 | 2024-07-17 | Ф. Хоффманн-Ля Рош Аг | Біспецифічне антитіло, яке специфічно зв'язується з pd1 і lag3 |
| PL3606954T3 (pl) | 2017-04-05 | 2022-10-17 | F. Hoffmann-La Roche Ag | Przeciwciała anty-LAG3 |
| WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| WO2018210898A1 (en) | 2017-05-18 | 2018-11-22 | F. Hoffmann-La Roche Ag | Reduction of application-related side reaction of a therapeutic antibody |
| MX2019014577A (es) | 2017-06-05 | 2020-07-29 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y metodos de uso. |
| WO2018224609A1 (en) | 2017-06-07 | 2018-12-13 | Genmab B.V. | Therapeutic antibodies based on mutated igg hexamers |
| UY37758A (es) | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
| MA49457A (fr) | 2017-06-22 | 2020-04-29 | Novartis Ag | Molécules d'anticorps se liant à cd73 et leurs utilisations |
| CN111050791A (zh) | 2017-06-27 | 2020-04-21 | 诺华股份有限公司 | 用于抗tim-3抗体的给药方案及其用途 |
| KR102714165B1 (ko) | 2017-07-11 | 2024-10-10 | 콤파스 테라퓨틱스 엘엘씨 | 인간 cd137에 결합하는 작동자 항체 및 이의 용도 |
| US20200172617A1 (en) | 2017-07-20 | 2020-06-04 | Novartis Ag | Dosage regimens of anti-lag-3 antibodies and uses thereof |
| CN107325184A (zh) * | 2017-08-08 | 2017-11-07 | 安徽大学 | 一种靶向egfr和her2的双特异性抗体及其应用 |
| CN118562014A (zh) | 2017-08-09 | 2024-08-30 | 美勒斯公司 | 结合EGFR和cMET的抗体 |
| TW201932142A (zh) | 2017-10-20 | 2019-08-16 | 瑞士商赫孚孟拉羅股份公司 | 自單特異性抗體產生多特異性抗體之方法 |
| US11161911B2 (en) | 2017-10-23 | 2021-11-02 | Go Therapeutics, Inc. | Anti-glyco-MUC1 antibodies and their uses |
| KR20200074195A (ko) | 2017-10-30 | 2020-06-24 | 에프. 호프만-라 로슈 아게 | 단일특이적 항체로부터 다중특이적 항체의 생체내 생성 방법 |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| US20210179709A1 (en) | 2017-10-31 | 2021-06-17 | Novartis Ag | Anti-car compositions and methods |
| MX2020004573A (es) | 2017-11-01 | 2020-09-25 | Hoffmann La Roche | Terapia de combinacion con agonistas de ox40 dirigidos. |
| CN111182944B (zh) | 2017-11-01 | 2022-11-22 | 豪夫迈·罗氏有限公司 | 双特异性2+1 Contorsbody |
| MX2020004756A (es) | 2017-11-16 | 2020-08-20 | Novartis Ag | Terapias de combinacion. |
| US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| EP3717916A1 (en) | 2017-11-29 | 2020-10-07 | H. Hoffnabb-La Roche Ag | Target interference suppressed anti-drug antibody assay |
| MX2020006119A (es) | 2017-12-21 | 2020-08-24 | Hoffmann La Roche | Anticuerpos de union a hla-a2/wt1. |
| WO2019122054A1 (en) | 2017-12-22 | 2019-06-27 | F. Hoffmann-La Roche Ag | Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography |
| CN111511400A (zh) | 2017-12-29 | 2020-08-07 | 豪夫迈·罗氏有限公司 | 抗vegf抗体及其使用方法 |
| SG11202006410WA (en) | 2018-01-12 | 2020-08-28 | Genzyme Corp | Methods for the quantitation of polypeptides |
| WO2019152660A1 (en) | 2018-01-31 | 2019-08-08 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| JP2021511782A (ja) | 2018-01-31 | 2021-05-13 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 安定化された免疫グロブリンドメイン |
| US20200354457A1 (en) | 2018-01-31 | 2020-11-12 | Hoffmann-La Roche Inc. | Bispecific antibodies comprising an antigen-binding site binding to lag3 |
| JP7475275B2 (ja) | 2018-02-08 | 2024-04-26 | ジェネンテック， インコーポレイテッド | 二重特異性抗原結合分子及びその使用方法 |
| TWI829667B (zh) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
| KR20200132913A (ko) | 2018-03-13 | 2020-11-25 | 에프. 호프만-라 로슈 아게 | 4-1bb 작용제와 항-cd20 항체의 치료 조합 |
| TWI841551B (zh) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
| JP2021519073A (ja) | 2018-03-29 | 2021-08-10 | ジェネンテック， インコーポレイテッド | 哺乳動物細胞におけるラクトジェニック活性の制御 |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| AR114789A1 (es) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
| AR115052A1 (es) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | Anticuerpos multiespecíficos y utilización de los mismos |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| CN112166196A (zh) | 2018-05-18 | 2021-01-01 | 豪夫迈·罗氏有限公司 | 大核酸的靶向细胞内递送 |
| WO2019226658A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Multispecific antigen-binding compositions and methods of use |
| US20200109195A1 (en) | 2018-05-21 | 2020-04-09 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by nk cells |
| ES2945214T3 (es) | 2018-05-23 | 2023-06-29 | Celgene Corp | Compuestos antiproliferativos y anticuerpo biespecífico contra BCMA y CD3 para uso combinado |
| KR20210012007A (ko) | 2018-05-24 | 2021-02-02 | 얀센 바이오테크 인코포레이티드 | 항-cd3 항체 및 이의 용도 |
| AU2019274657A1 (en) | 2018-05-24 | 2020-12-10 | Janssen Biotech, Inc. | PSMA binding agents and uses thereof |
| PE20210634A1 (es) | 2018-05-24 | 2021-03-23 | Janssen Biotech Inc | Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos |
| EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| CN112243444A (zh) | 2018-06-08 | 2021-01-19 | 豪夫迈·罗氏有限公司 | 具有减少的翻译后修饰的肽接头 |
| BR112020025048A2 (pt) | 2018-06-13 | 2021-04-06 | Novartis Ag | Receptores de antígeno quimérico de bcma e usos dos mesmos |
| BR112020026033A2 (pt) | 2018-06-19 | 2021-03-23 | Atarga, Llc | moléculas de anticorpo para complementar o componente 5 e usos das mesmas |
| MX2020013804A (es) * | 2018-06-21 | 2021-03-31 | Regeneron Pharma | Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos. |
| JP2021528988A (ja) | 2018-07-04 | 2021-10-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 新規の二重特異性アゴニスト４−１ｂｂ抗原結合分子 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| TWI754157B (zh) | 2018-07-25 | 2022-02-01 | 大陸商信達生物製藥（蘇州）有限公司 | 抗ｔｉｇｉｔ抗體及其用途 |
| WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
| MA50586A (fr) | 2018-08-09 | 2020-09-16 | Regeneron Pharma | Procédés d'évaluation de l'affinité de liaison d'une variante d'anticorps au récepteur fc néonatal |
| JP7221379B2 (ja) | 2018-10-01 | 2023-02-13 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｆａｐクローン２１２を含む二重特異性抗原結合分子 |
| CN112654641A (zh) | 2018-10-01 | 2021-04-13 | 豪夫迈·罗氏有限公司 | 具有与cd40的三价结合的双特异性抗原结合分子 |
| JP7522106B2 (ja) | 2018-10-04 | 2024-07-24 | ジェンマブ ホールディング ビー．ブイ． | 二重特異性抗ｃｄ３７抗体を含む医薬組成物 |
| CN112912392B (zh) | 2018-10-26 | 2024-08-02 | 豪夫迈·罗氏有限公司 | 利用重组酶介导的盒式交换的多特异性抗体筛选方法 |
| WO2020089437A1 (en) | 2018-10-31 | 2020-05-07 | Engmab Sàrl | Combination therapy |
| US20210369842A1 (en) | 2018-11-06 | 2021-12-02 | Genmab A/S | Antibody formulation |
| SG11202104864QA (en) | 2018-11-13 | 2021-06-29 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
| WO2020128892A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Extended low dose regimens for mdm2 inhibitors |
| MX2021007392A (es) | 2018-12-20 | 2021-08-24 | Novartis Ag | Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
| SG11202106198YA (en) | 2018-12-21 | 2021-07-29 | Hoffmann La Roche | Antibody that binds to vegf and il-1beta and methods of use |
| US20200223925A1 (en) | 2018-12-21 | 2020-07-16 | Hoffmann-La Roche Inc. | Tumor-targeted superagonistic cd28 antigen binding molecules |
| MY194642A (en) | 2018-12-21 | 2022-12-09 | Hoffmann La Roche | Antibodies binding to cd3 |
| CR20210326A (es) | 2018-12-21 | 2021-09-10 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor |
| WO2020136060A1 (en) | 2018-12-28 | 2020-07-02 | F. Hoffmann-La Roche Ag | A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response |
| CN111378045B (zh) * | 2018-12-28 | 2022-08-02 | 长春金赛药业有限责任公司 | 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物 |
| EP3903102B1 (en) | 2018-12-30 | 2023-04-12 | F. Hoffmann-La Roche AG | Ph-gradient spr-based binding assay |
| US10871640B2 (en) | 2019-02-15 | 2020-12-22 | Perkinelmer Cellular Technologies Germany Gmbh | Methods and systems for automated imaging of three-dimensional objects |
| CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EA202192019A1 (ru) | 2019-02-15 | 2021-11-02 | Новартис Аг | Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения |
| WO2020172553A1 (en) | 2019-02-22 | 2020-08-27 | Novartis Ag | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
| BR112021016149A2 (pt) | 2019-02-26 | 2021-10-13 | Janssen Biotech, Inc. | Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met |
| MA55519A (fr) | 2019-03-29 | 2022-02-09 | Atarga Llc | Anticorps anti-fgf23 |
| JP7249432B2 (ja) | 2019-03-29 | 2023-03-30 | エフ． ホフマン－ラ ロシュ アーゲー | 多価分子の機能分析のための、ｓｐｒをベースとする結合アッセイ |
| CN113677701A (zh) | 2019-03-29 | 2021-11-19 | 豪夫迈·罗氏有限公司 | 产生亲合结合多特异性抗体的方法 |
| KR20220002899A (ko) | 2019-04-19 | 2022-01-07 | 얀센 바이오테크 인코포레이티드 | 항-psma/cd3 항체로 전립선암을 치료하는 방법 |
| SG11202112021QA (en) | 2019-05-08 | 2021-11-29 | Janssen Biotech Inc | Materials and methods for modulating t cell mediated immunity |
| BR112021022405A2 (pt) | 2019-05-09 | 2022-04-19 | Merus Nv | Domínios variantes para multimerização de proteínas e separação das mesmas |
| BR112021021673A2 (pt) | 2019-05-09 | 2021-12-21 | Genentech Inc | Método para melhorar o emparelhamento preferencial de uma cadeia pesada e uma cadeia leve de um anticorpo e anticorpo |
| EP3969907A1 (en) | 2019-05-13 | 2022-03-23 | F. Hoffmann-La Roche AG | Interference-suppressed pharmacokinetic immunoassay |
| WO2020230091A1 (en) | 2019-05-14 | 2020-11-19 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
| BR112021025500A2 (pt) | 2019-06-19 | 2022-02-01 | Hoffmann La Roche | Métodos para produzir um anticorpo multivalente biespecífico e para produzir uma célula de mamífero recombinante, ácido desoxirribonucleico, uso de um ácido desoxirribonucleico, célula de mamífero recombinante e composição |
| JP7572977B2 (ja) | 2019-06-19 | 2024-10-24 | エフ． ホフマン－ラ ロシュ アーゲー | 所定の構成の複数の発現カセットの標的化組込みによって多価の多重特異性抗体発現細胞を作製するための方法 |
| MX2021015536A (es) | 2019-06-19 | 2022-02-10 | Hoffmann La Roche | Metodo para la generacion de una celula que expresa proteina mediante integracion dirigida usando acido ribonucleico mensajero (arnm) de cre. |
| MX2021015540A (es) | 2019-06-19 | 2022-02-10 | Hoffmann La Roche | Metodo para la generacion de una celula que expresa un anticuerpo trivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida. |
| MX2021015538A (es) | 2019-06-19 | 2022-02-10 | Hoffmann La Roche | Metodo para la generacion de una celula que expresa un anticuerpo biespecifico bivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida. |
| AU2020306672B2 (en) | 2019-06-26 | 2023-08-24 | F. Hoffmann-La Roche Ag | Mammalian cell lines with SIRT-1 gene knockout |
| AR119393A1 (es) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
| EP4004045A1 (en) | 2019-07-31 | 2022-06-01 | F. Hoffmann-La Roche AG | Antibodies binding to gprc5d |
| PE20220394A1 (es) | 2019-07-31 | 2022-03-18 | Hoffmann La Roche | Anticuerpos que se fijan a gprc5d |
| WO2021048034A1 (en) | 2019-09-09 | 2021-03-18 | F. Hoffmann-La Roche Ag | Glucocerebrosidase mutants |
| PE20221906A1 (es) | 2019-09-18 | 2022-12-23 | Genentech Inc | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso |
| CN112574308A (zh) | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | 靶向bcma的抗体、双特异性抗体及其用途 |
| CN114786680A (zh) | 2019-10-21 | 2022-07-22 | 诺华股份有限公司 | Tim-3抑制剂及其用途 |
| US20240301053A1 (en) | 2019-10-21 | 2024-09-12 | Novartis Ag | Combination therapies with venetoclax and tim-3 inhibitors |
| AU2020384917A1 (en) | 2019-11-15 | 2022-03-31 | F. Hoffmann-La Roche Ag | Prevention of visible particle formation in aqueous protein solutions |
| BR112022010206A2 (pt) | 2019-11-26 | 2022-11-29 | Novartis Ag | Receptores de antígeno quiméricos e usos dos mesmos |
| KR20220113791A (ko) | 2019-12-18 | 2022-08-16 | 에프. 호프만-라 로슈 아게 | 이중특이적 항-ccl2 항체 |
| WO2021122875A1 (en) | 2019-12-18 | 2021-06-24 | F. Hoffmann-La Roche Ag | Antibodies binding to hla-a2/mage-a4 |
| EP4077389A1 (en) | 2019-12-20 | 2022-10-26 | Novartis AG | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
| CN115515678A (zh) | 2019-12-23 | 2022-12-23 | 基因泰克公司 | 载脂蛋白l1特异性抗体及其使用方法 |
| US11913945B2 (en) | 2020-01-02 | 2024-02-27 | Hoffmann-La Roche Inc. | Method for determining the amount of a therapeutic antibody in the brain |
| KR20220129003A (ko) | 2020-01-15 | 2022-09-22 | 에프. 호프만-라 로슈 아게 | 재조합 단백질 제조 공정으로부터 불순물을 감소시키기 위한 방법 |
| TW202140037A (zh) | 2020-01-17 | 2021-11-01 | 瑞士商諾華公司 | 組合療法 |
| EP4090762A1 (en) | 2020-01-17 | 2022-11-23 | Becton, Dickinson and Company | Methods and compositions for single cell secretomics |
| JP2023515211A (ja) | 2020-02-27 | 2023-04-12 | ノバルティス アーゲー | キメラ抗原受容体発現細胞を作製する方法 |
| CN115315446A (zh) | 2020-03-06 | 2022-11-08 | Go医疗股份有限公司 | 抗糖-cd44抗体及其用途 |
| KR20220159426A (ko) | 2020-03-26 | 2022-12-02 | 제넨테크, 인크. | 감소된 숙주 세포 단백질을 보유하는 변형된 포유동물 세포 |
| WO2021198034A1 (en) | 2020-03-30 | 2021-10-07 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf and pdgf-b and methods of use |
| AR121706A1 (es) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
| CA3180173A1 (en) | 2020-04-30 | 2021-11-04 | Bristol-Myers Squibb Company | Methods of treating cytokine-related adverse events |
| CN115605184A (zh) | 2020-05-15 | 2023-01-13 | 豪夫迈·罗氏有限公司（Ch） | 防止胃肠外蛋白质溶液中的可见颗粒形成 |
| EP4153130A1 (en) | 2020-05-19 | 2023-03-29 | F. Hoffmann-La Roche AG | The use of chelators for the prevention of visible particle formation in parenteral protein solutions |
| CN115666723A (zh) | 2020-05-21 | 2023-01-31 | 美勒斯公司 | 用于生产ig样分子的方法和手段 |
| WO2021249990A2 (en) | 2020-06-08 | 2021-12-16 | Hoffmann-La Roche Inc. | Anti-hbv antibodies and methods of use |
| MX2022015899A (es) | 2020-06-16 | 2023-01-24 | Hoffmann La Roche | Metodo para determinar antigeno libre de un anticuerpo en una muestra. |
| CR20220637A (es) | 2020-06-19 | 2023-01-31 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y cd19 |
| WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
| CN115916826A (zh) | 2020-06-19 | 2023-04-04 | 豪夫迈·罗氏有限公司 | 与CD3和FolR1结合的抗体 |
| WO2021255142A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 |
| US12049515B2 (en) | 2020-06-23 | 2024-07-30 | Hoffmann-La Roche Inc. | Agonistic CD28 antigen binding molecules targeting Her2 |
| MX2022015852A (es) | 2020-06-23 | 2023-01-24 | Novartis Ag | Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
| CN115943158A (zh) | 2020-06-24 | 2023-04-07 | 基因泰克公司 | 抗细胞凋亡的细胞系 |
| JP2023531067A (ja) | 2020-06-25 | 2023-07-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｃｄ３／抗ｃｄ２８二重特異性抗原結合分子 |
| JP2023531670A (ja) | 2020-06-30 | 2023-07-25 | 諾納生物（蘇州）有限公司 | 抗ｂ７ｈ４抗体及びその二重特異性抗体および用途 |
| EP4155318A4 (en) | 2020-06-30 | 2024-06-05 | Harbour Biomed US, Inc. | BISPECIFIC ANTIBODY AND USE THEREOF |
| CN116133689A (zh) | 2020-07-07 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 作为治疗性蛋白质制剂的稳定剂的替代表面活性剂 |
| AU2021308712A1 (en) | 2020-07-16 | 2023-02-02 | Novartis Ag | Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules |
| CR20230087A (es) | 2020-07-17 | 2023-03-20 | Genentech Inc | Anticuerpos anti-notch2 y métodos de uso |
| AU2021311034A1 (en) | 2020-07-24 | 2023-02-23 | F. Hoffmann-La Roche Ag | Method for the expression of an antibody-multimer-fusion |
| WO2022026592A2 (en) | 2020-07-28 | 2022-02-03 | Celltas Bio, Inc. | Antibody molecules to coronavirus and uses thereof |
| JP2023536164A (ja) | 2020-08-03 | 2023-08-23 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| CN116648507A (zh) | 2020-08-28 | 2023-08-25 | 基因泰克公司 | 宿主细胞蛋白的CRISPR/Cas9多重敲除 |
| WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| EP4208201A1 (en) | 2020-09-04 | 2023-07-12 | F. Hoffmann-La Roche AG | Antibody that binds to vegf-a and ang2 and methods of use |
| MX2023003127A (es) | 2020-09-21 | 2023-03-23 | Genentech Inc | Purificacion de anticuerpos multiespecificos. |
| KR20230068415A (ko) | 2020-09-24 | 2023-05-17 | 에프. 호프만-라 로슈 아게 | 유전자 녹아웃을 갖는 포유류 세포주 |
| WO2022086957A1 (en) | 2020-10-20 | 2022-04-28 | Genentech, Inc. | Peg-conjugated anti-mertk antibodies and methods of use |
| TW202233674A (zh) | 2020-10-28 | 2022-09-01 | 美商健生生物科技公司 | 用於調節δγ鏈介導之免疫的組成物及方法 |
| US20240002509A1 (en) | 2020-11-06 | 2024-01-04 | Novartis Ag | ANTIBODY Fc VARIANTS |
| EP4243857A1 (en) | 2020-11-13 | 2023-09-20 | Novartis AG | Combination therapies with chimeric antigen receptor (car)-expressing cells |
| WO2022101458A1 (en) | 2020-11-16 | 2022-05-19 | F. Hoffmann-La Roche Ag | Combination therapy with fap-targeted cd40 agonists |
| EP4261225A4 (en) | 2020-12-10 | 2024-11-13 | Eutilex Co Ltd | ANTI-PD-1 ANTIBODIES AND USES THEREOF |
| KR20230120665A (ko) | 2020-12-17 | 2023-08-17 | 에프. 호프만-라 로슈 아게 | 항-hla-g 항체 및 이의 용도 |
| CN116670282A (zh) | 2020-12-22 | 2023-08-29 | 豪夫迈·罗氏有限公司 | 靶向xbp1的寡核苷酸 |
| WO2022135467A1 (zh) | 2020-12-23 | 2022-06-30 | 信达生物制药(苏州)有限公司 | 抗b7-h3抗体及其用途 |
| CN114716548B (zh) | 2021-01-05 | 2024-11-05 | (株)爱恩德生物 | 抗-fgfr3抗体及其用途 |
| KR20230117406A (ko) | 2021-01-06 | 2023-08-08 | 에프. 호프만-라 로슈 아게 | Pd1-lag3 이중특이성 항체와 cd20 t 세포 이중특이성항체를 이용한 조합 요법 |
| EP4284838A2 (en) | 2021-01-28 | 2023-12-06 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
| US20240141060A1 (en) | 2021-01-29 | 2024-05-02 | Novartis Ag | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
| CA3209479A1 (en) | 2021-02-03 | 2022-08-11 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| EP4288458A1 (en) | 2021-02-03 | 2023-12-13 | Genentech, Inc. | Multispecific binding protein degrader platform and methods of use |
| AU2022217845A1 (en) | 2021-02-04 | 2023-08-24 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-tnfr2 antibody and use thereof |
| CN116888473A (zh) | 2021-02-18 | 2023-10-13 | 豪夫迈·罗氏有限公司 | 用于解析复杂、多步骤抗体相互作用的方法 |
| WO2022187591A1 (en) | 2021-03-05 | 2022-09-09 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| US20220298248A1 (en) | 2021-03-09 | 2022-09-22 | Janssen Biotech, Inc. | Treatment of Cancers Lacking EGFR- Activating Mutations |
| EP4304732A1 (en) | 2021-03-12 | 2024-01-17 | Genentech, Inc. | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| EP4320444A1 (en) | 2021-04-09 | 2024-02-14 | F. Hoffmann-La Roche AG | Process for selecting cell clones expressing a heterologous polypeptide |
| US20240209080A1 (en) | 2021-04-10 | 2024-06-27 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
| JP2024514222A (ja) | 2021-04-19 | 2024-03-28 | ジェネンテック， インコーポレイテッド | 改変された哺乳動物細胞 |
| WO2022226317A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
| IL307821A (en) | 2021-04-30 | 2023-12-01 | Hoffmann La Roche | Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody |
| WO2022228705A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| TW202309094A (zh) | 2021-05-18 | 2023-03-01 | 美商健生生物科技公司 | 用於識別癌症患者以進行組合治療之方法 |
| WO2022243261A1 (en) | 2021-05-19 | 2022-11-24 | F. Hoffmann-La Roche Ag | Agonistic cd40 antigen binding molecules targeting cea |
| EP4341385A1 (en) | 2021-05-21 | 2024-03-27 | Genentech, Inc. | Modified cells for the production of a recombinant product of interest |
| CN113278071B (zh) | 2021-05-27 | 2021-12-21 | 江苏荃信生物医药股份有限公司 | 抗人干扰素α受体1单克隆抗体及其应用 |
| AR126009A1 (es) | 2021-06-02 | 2023-08-30 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam |
| TWI833244B (zh) | 2021-06-18 | 2024-02-21 | 大陸商和鉑醫藥（上海）有限責任公司 | 一種雙抗組合及其應用 |
| CA3221735A1 (en) | 2021-06-18 | 2022-12-22 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
| AU2022302170A1 (en) | 2021-07-02 | 2023-12-21 | F. Hoffmann-La Roche Ag | Methods and compositions for treating cancer |
| KR20240032930A (ko) | 2021-07-13 | 2024-03-12 | 제넨테크, 인크. | 사이토카인 방출 증후군을 예측하기 위한 다변량 모델 |
| JP2024528631A (ja) | 2021-07-22 | 2024-07-30 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | ヘテロ二量体Ｆｃドメイン抗体 |
| WO2023010095A1 (en) | 2021-07-28 | 2023-02-02 | F. Hoffmann-La Roche Ag | Methods and compositions for treating cancer |
| CN117794953A (zh) | 2021-08-03 | 2024-03-29 | 豪夫迈·罗氏有限公司 | 双特异性抗体及使用方法 |
| EP4380604A1 (en) | 2021-08-05 | 2024-06-12 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
| KR20240044467A (ko) | 2021-08-09 | 2024-04-04 | 하버 바이오메드 (상하이) 컴퍼니 리미티드 | Cldn18.2-표적화 항체, 이중특이적 항체, 및 이들의 용도 |
| CN113603775B (zh) | 2021-09-03 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素-33单克隆抗体及其应用 |
| CN118355031A (zh) | 2021-09-03 | 2024-07-16 | Go医疗股份有限公司 | 抗糖-lamp1抗体及其用途 |
| CN113683694B (zh) | 2021-09-03 | 2022-05-13 | 江苏荃信生物医药股份有限公司 | 一种抗人tslp单克隆抗体及其应用 |
| JP2024536722A (ja) | 2021-09-03 | 2024-10-08 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｃｍｅｔ抗体およびその使用 |
| EP4148067A1 (en) | 2021-09-08 | 2023-03-15 | F. Hoffmann-La Roche AG | Method for the expression of an antibody-multimer-fusion |
| EP4405396A2 (en) | 2021-09-20 | 2024-07-31 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2023094282A1 (en) | 2021-11-25 | 2023-06-01 | F. Hoffmann-La Roche Ag | Quantification of low amounts of antibody sideproducts |
| US20230183360A1 (en) | 2021-12-09 | 2023-06-15 | Janssen Biotech, Inc. | Use of Amivantamab to Treat Colorectal Cancer |
| AR127887A1 (es) | 2021-12-10 | 2024-03-06 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y plap |
| CR20240246A (es) | 2021-12-20 | 2024-07-19 | Hoffmann La Roche | Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden |
| WO2023117325A1 (en) | 2021-12-21 | 2023-06-29 | F. Hoffmann-La Roche Ag | Method for the determination of hydrolytic activity |
| EP4457342A1 (en) | 2021-12-29 | 2024-11-06 | Bristol-Myers Squibb Company | Generation of landing pad cell lines |
| TW202340251A (zh) | 2022-01-19 | 2023-10-16 | 美商建南德克公司 | 抗ｎｏｔｃｈ２抗體及結合物及其使用方法 |
| US20230383010A1 (en) | 2022-02-07 | 2023-11-30 | Visterra, Inc. | Anti-idiotype antibody molecules and uses thereof |
| TW202342057A (zh) | 2022-02-07 | 2023-11-01 | 美商健生生物科技公司 | 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法 |
| IL314211A (en) | 2022-03-23 | 2024-09-01 | Genentech Inc | Combined treatment of bispecific antibody and chemotherapy against CD20/ANTI-CD3 |
| IL315526A (en) | 2022-03-29 | 2024-11-01 | Ngm Biopharmaceuticals Inc | ILT3 and CD3 binding agents and methods of using them |
| WO2023198661A1 (en) | 2022-04-12 | 2023-10-19 | F. Hoffmann-La Roche Ag | Fusion proteins targeted to the central nervous system |
| WO2023198727A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
| WO2023202967A1 (en) | 2022-04-19 | 2023-10-26 | F. Hoffmann-La Roche Ag | Improved production cells |
| AR129268A1 (es) | 2022-05-11 | 2024-08-07 | Hoffmann La Roche | Anticuerpo que se une a vegf-a e il6 y métodos de uso |
| WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2023232961A1 (en) | 2022-06-03 | 2023-12-07 | F. Hoffmann-La Roche Ag | Improved production cells |
| WO2024003837A1 (en) | 2022-06-30 | 2024-01-04 | Janssen Biotech, Inc. | Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer |
| WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
| WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| WO2024030956A2 (en) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
| WO2024030976A2 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
| TW202423970A (zh) | 2022-10-10 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法 |
| WO2024079074A1 (en) | 2022-10-10 | 2024-04-18 | Universite D'aix Marseille | ANTI-sCD146 ANTIBODIES AND USES THEREOF |
| TW202423969A (zh) | 2022-10-10 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法 |
| TW202430211A (zh) | 2022-10-10 | 2024-08-01 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法 |
| WO2024079069A1 (en) | 2022-10-12 | 2024-04-18 | F. Hoffmann-La Roche Ag | Method for classifying cells |
| WO2024089551A1 (en) | 2022-10-25 | 2024-05-02 | Janssen Biotech, Inc. | Msln and cd3 binding agents and methods of use thereof |
| WO2024094741A1 (en) | 2022-11-03 | 2024-05-10 | F. Hoffmann-La Roche Ag | Combination therapy with anti-cd19/anti-cd28 bispecific antibody |
| WO2024110426A1 (en) | 2022-11-23 | 2024-05-30 | F. Hoffmann-La Roche Ag | Method for increasing recombinant protein expression |
| WO2024129594A1 (en) | 2022-12-12 | 2024-06-20 | Genentech, Inc. | Optimizing polypeptide sialic acid content |
| WO2024156672A1 (en) | 2023-01-25 | 2024-08-02 | F. Hoffmann-La Roche Ag | Antibodies binding to csf1r and cd3 |
| WO2024163009A1 (en) | 2023-01-31 | 2024-08-08 | Genentech, Inc. | Methods and compositions for treating urothelial bladder cancer |
| WO2024163494A1 (en) | 2023-01-31 | 2024-08-08 | F. Hoffmann-La Roche Ag | Methods and compositions for treating non-small cell lung cancer and triple-negative breast cancer |
| WO2024168061A2 (en) | 2023-02-07 | 2024-08-15 | Ayan Therapeutics Inc. | Antibody molecules binding to sars-cov-2 |
| WO2024184287A1 (en) | 2023-03-06 | 2024-09-12 | F. Hoffmann-La Roche Ag | Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist |
| WO2024191785A1 (en) | 2023-03-10 | 2024-09-19 | Genentech, Inc. | Fusions with proteases and uses thereof |
| WO2024188965A1 (en) | 2023-03-13 | 2024-09-19 | F. Hoffmann-La Roche Ag | Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody |
| WO2024189544A1 (en) | 2023-03-13 | 2024-09-19 | Janssen Biotech, Inc. | Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies |
| US20240327522A1 (en) | 2023-03-31 | 2024-10-03 | Genentech, Inc. | Anti-alpha v beta 8 integrin antibodies and methods of use |
Family Cites Families (222)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| US6511663B1 (en) | 1991-06-11 | 2003-01-28 | Celltech R&D Limited | Tri- and tetra-valent monospecific antigen-binding proteins |
| JP3951062B2 (ja) * | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用 |
| EP0614375A1 (en) | 1991-11-26 | 1994-09-14 | Alkermes, Inc. | Process for the preparation of transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
| GB9221657D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
| ES2278663T3 (es) | 1992-10-28 | 2007-08-16 | Genentech, Inc. | Antagonistas del factor de crecimiento de celulas endoteliales vasculares vegf. |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| US6476198B1 (en) | 1993-07-13 | 2002-11-05 | The Scripps Research Institute | Multispecific and multivalent antigen-binding polypeptide molecules |
| UA40577C2 (ru) | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Биспецифическая молекула, которая используется для лизиса опухолевых клеток, способ ее получения, моноклональное антитело (варианты), фармацевтический препарат, фармацевтический набор (варианты), способ удаления опухолевых клеток |
| WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| GB9504344D0 (en) | 1995-03-03 | 1995-04-19 | Unilever Plc | Antibody fragment production |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| EP0894135B1 (en) | 1996-04-04 | 2004-08-11 | Unilever Plc | Multivalent and multispecific antigen-binding protein |
| DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
| WO1998045332A2 (en) | 1997-04-07 | 1998-10-15 | Genentech, Inc. | Humanized antibodies and methods for forming humanized antibodies |
| WO1998050431A2 (en) | 1997-05-02 | 1998-11-12 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| AU2719099A (en) * | 1998-01-23 | 1999-08-09 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Multipurpose antibody derivatives |
| ES2340112T3 (es) | 1998-04-20 | 2010-05-28 | Glycart Biotechnology Ag | Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos. |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| ATE460946T1 (de) | 1998-06-22 | 2010-04-15 | Immunomedics Inc | Gebrauch von bispezifischen antikörpern in diagnose und therapie |
| US7138103B2 (en) | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
| US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
| AU1687500A (en) | 1998-12-16 | 2000-07-03 | Kyowa Hakko Kogyo Co. Ltd. | Antihuman vegf monoclonal antibody |
| US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
| CN1232039A (zh) | 1999-04-02 | 1999-10-20 | 中国人民解放军海军总医院 | 一种基因工程双特异抗体及其应用 |
| EP2278003B2 (en) | 1999-04-09 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CN1423700A (zh) | 2000-03-24 | 2003-06-11 | 麦克美特股份公司 | 含有针对nkg2d受体复合物的表位的结合位点的多功能多肽 |
| IL151853A0 (en) | 2000-04-11 | 2003-04-10 | Genentech Inc | Multivalent antibodies and uses therefor |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| EP1299419A2 (en) | 2000-05-24 | 2003-04-09 | Imclone Systems, Inc. | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| WO2002002781A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| RU2295537C2 (ru) * | 2000-10-20 | 2007-03-20 | Тугаи Сейяку Кабусики Кайся | Модифицированное агонистическое антитело |
| AU2002210918B2 (en) | 2000-10-20 | 2006-03-16 | Chugai Seiyaku Kabushiki Kaisha | Degraded agonist antibody |
| US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
| US20030099974A1 (en) | 2001-07-18 | 2003-05-29 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer |
| ATE346866T1 (de) | 2001-09-14 | 2006-12-15 | Affimed Therapeutics Ag | Multimerische, einzelkettige, tandem-fv- antikörper |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
| AU2002337935B2 (en) | 2001-10-25 | 2008-05-01 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| JP2006502091A (ja) | 2002-03-01 | 2006-01-19 | イミューノメディクス、インコーポレイテッド | クリアランス速度を高めるための二重特異性抗体点変異 |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| EP1497332A1 (en) | 2002-04-29 | 2005-01-19 | GenPat77 Pharmacogenetics AG | Bispecific antibody binding tcr and tirc7 and its use in therapy and diagnosis |
| US7081443B2 (en) | 2002-05-21 | 2006-07-25 | Korea Advanced Institutes Of Science And Technology (Kaist) | Chimeric comp-ang1 molecule |
| EP2135879A3 (en) | 2002-06-28 | 2010-06-23 | Domantis Limited | Ligand |
| HUE025086T2 (en) | 2002-10-10 | 2016-02-29 | Merck Patent Gmbh | Pharmaceutical preparations for ERB-B1 receptor |
| US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| SG179292A1 (en) | 2003-01-22 | 2012-04-27 | Roche Glycart Ag | Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function |
| BRPI0407446A (pt) | 2003-02-13 | 2006-01-31 | Pharmacia Corp | Anticorpos para c-met para o tratamento de cânceres |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| AU2004251168A1 (en) | 2003-05-30 | 2005-01-06 | Genentech, Inc. | Treatment with anti-VEGF antibodies |
| WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
| AU2004252171B2 (en) | 2003-06-27 | 2011-04-21 | Biogen Ma Inc. | Modified binding molecules comprising connecting peptides |
| US20050100543A1 (en) | 2003-07-01 | 2005-05-12 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| AR046071A1 (es) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| CA2534077A1 (en) | 2003-07-29 | 2005-02-10 | Morphotek Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| CA2536408A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| JP2007504245A (ja) | 2003-09-05 | 2007-03-01 | ジェネンテック・インコーポレーテッド | 変更したエフェクター機能を有する抗体 |
| US20050064509A1 (en) | 2003-09-23 | 2005-03-24 | The Regents Of The University Of California | Use of templated self assembly to create novel multifunctional species |
| CN1326881C (zh) | 2003-09-29 | 2007-07-18 | 中国人民解放军军事医学科学院基础医学研究所 | 一种三价双特异性抗体，其制备方法及用途 |
| NZ588860A (en) | 2003-11-05 | 2012-03-30 | Roche Glycart Ag | CD20 antibodies with increased Fc receptor binding affinity and effector function |
| ES2305879T3 (es) | 2003-11-21 | 2008-11-01 | Ucb Pharma, S.A. | Metodo para el tratamiento de la esclerosis multiple mediante inhibicion de la actividad il-17. |
| ZA200604864B (en) | 2003-12-19 | 2007-10-31 | Genentech Inc | Monovalent antibody fragments useful as therapeutics |
| US20080187954A1 (en) | 2004-03-10 | 2008-08-07 | Lonza Ltd. | Method For Producing Antibodies |
| CA2561264A1 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| WO2006020258A2 (en) | 2004-07-17 | 2006-02-23 | Imclone Systems Incorporated | Novel tetravalent bispecific antibody |
| RU2367667C2 (ru) | 2004-08-19 | 2009-09-20 | Дженентек, Инк. | Полипептидные варианты с измененной эффекторной функцией |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2007024249A2 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
| US7973140B2 (en) | 2004-12-21 | 2011-07-05 | Medimmune Limited | Antibodies directed to angiopoietin-2 and uses thereof |
| TWI387602B (zh) | 2005-02-07 | 2013-03-01 | Roche Glycart Ag | 與上皮生長因子受體（ｅｇｆｒ）結合之抗原結合分子，編碼該抗原結合分子之載體及其用途 |
| AU2005327973A1 (en) | 2005-02-23 | 2006-08-31 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
| CN101218251A (zh) | 2005-02-28 | 2008-07-09 | 森托科尔公司 | 异二聚体蛋白结合组合物 |
| EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| EP1870458B1 (en) | 2005-03-31 | 2018-05-09 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2 STRUCTURAL ISOMERS |
| TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
| EP1868650B1 (en) | 2005-04-15 | 2018-10-03 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| CA2606102C (en) | 2005-04-26 | 2014-09-30 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
| JP5315489B2 (ja) | 2005-04-26 | 2013-10-16 | アール クレア アンド カンパニー | エフェクター機能が増強されたヒトＩｇＧ抗体を作製する方法 |
| JP5085322B2 (ja) | 2005-06-10 | 2012-11-28 | 中外製薬株式会社 | ｓｃ（Ｆｖ）２を含有する医薬組成物 |
| CA2611726C (en) | 2005-06-10 | 2017-07-11 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(fv)2 |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| WO2007024715A2 (en) | 2005-08-19 | 2007-03-01 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| RU2482132C2 (ru) | 2005-08-26 | 2013-05-20 | Роше Гликарт Аг | Модифицированные антигенсвязывающие молекулы с измененной клеточной сигнальной активностью |
| WO2007044887A2 (en) | 2005-10-11 | 2007-04-19 | Transtarget, Inc. | Method for producing a population of homogenous tetravalent bispecific antibodies |
| US7666622B2 (en) | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
| TW200732350A (en) | 2005-10-21 | 2007-09-01 | Amgen Inc | Methods for generating monovalent IgG |
| NZ569787A (en) | 2005-12-15 | 2011-07-29 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLT1 antagonist for treating cancer |
| FR2894959B1 (fr) | 2005-12-15 | 2008-02-29 | Galderma Res & Dev | Derives biphenyliques agonistes selectifs du recepteur rar-gamma |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| KR20080106245A (ko) | 2006-02-15 | 2008-12-04 | 임클론 시스템즈 인코포레이티드 | 기능성 항체 |
| CA2638804C (en) | 2006-03-03 | 2017-02-28 | Tokyo University Of Science | Modified antibodies with enhanced biological activities |
| CA2646508A1 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| EP1996236A2 (en) | 2006-03-22 | 2008-12-03 | National Institute of Immunology | Novel bioconjugates as therapeutic agent and synthesis thereof |
| JP5474531B2 (ja) | 2006-03-24 | 2014-04-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 操作されたヘテロ二量体タンパク質ドメイン |
| US20070274985A1 (en) | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
| WO2007146959A2 (en) | 2006-06-12 | 2007-12-21 | Receptor Biologix Inc. | Pan-cell surface receptor- specific therapeutics |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| WO2008005828A2 (en) | 2006-06-30 | 2008-01-10 | Novo Nordisk A/S | PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS COMPRISING ANTIBODY MOLECULES SPECIFIC TO LAMININ-5 α3 CHAIN DOMAINS G1G2 AND USE THEREOF |
| AR062223A1 (es) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
| US8497246B2 (en) | 2006-08-18 | 2013-07-30 | Armagen Technologies, Inc. | Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions |
| EP2059533B1 (en) | 2006-08-30 | 2012-11-14 | Genentech, Inc. | Multispecific antibodies |
| CN101205255A (zh) | 2006-12-14 | 2008-06-25 | 上海中信国健药业有限公司 | 抗cd20四价抗体、其制备方法和应用 |
| SG176448A1 (en) | 2006-12-19 | 2011-12-29 | Genentech Inc | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| PL2716301T3 (pl) | 2007-02-16 | 2017-10-31 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
| US10259860B2 (en) | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
| EP2069401A4 (en) | 2007-07-31 | 2011-02-23 | Medimmune Llc | MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE |
| WO2009023843A1 (en) | 2007-08-15 | 2009-02-19 | Isp Investments Inc. | Polyvinylamide polymers containing polymerizable functionalities |
| US9624309B2 (en) | 2007-08-15 | 2017-04-18 | Bayer Intellectual Property Gmbh | Monospecific and multispecific antibodies and method of use |
| DE102007038753A1 (de) | 2007-08-16 | 2009-02-19 | Giesecke & Devrient Gmbh | Vorrichtung und Verfahren für die Kalibrierung eines Sensorsystems |
| US20090130105A1 (en) | 2007-08-28 | 2009-05-21 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of igf-1r |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
| JP2009181819A (ja) | 2008-01-31 | 2009-08-13 | Hitachi High-Technologies Corp | 荷電粒子線装置 |
| JP4438875B2 (ja) | 2008-02-27 | 2010-03-24 | 三菱自動車工業株式会社 | 車両の貯蔵燃料量推定装置 |
| WO2009126944A1 (en) | 2008-04-11 | 2009-10-15 | Trubion Pharmaceuticals, Inc. | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| NZ603698A (en) | 2008-07-08 | 2014-03-28 | Abbvie Inc | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| CA2736408A1 (en) | 2008-09-26 | 2010-04-01 | Roche Glycart Ag | Bispecific anti-egfr/anti-igf-1r antibodies |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| KR20110097913A (ko) | 2008-12-04 | 2011-08-31 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| MA33198B1 (fr) | 2009-03-20 | 2012-04-02 | Genentech Inc | Anticorps anti-her di-spécifiques |
| CA2756244A1 (en) | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
| WO2010112194A1 (en) | 2009-04-02 | 2010-10-07 | F. Hoffmann-La Roche Ag | Antigen-binding polypeptides and multispecific antibodies comprising them |
| SG175078A1 (en) | 2009-04-07 | 2011-11-28 | Roche Glycart Ag | Bispecific anti-erbb-1/anti-c-met antibodies |
| MX2011010168A (es) | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos, trivalentes. |
| MX2011010166A (es) | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-3/anti-c-met. |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| TW201100543A (en) | 2009-05-27 | 2011-01-01 | Hoffmann La Roche | Tri-or tetraspecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| RU2015153109A (ru) | 2009-09-16 | 2019-01-15 | Дженентек, Инк. | Содержащие суперспираль и/или привязку белковые комплексы и их применения |
| MX2012003598A (es) | 2009-09-29 | 2012-04-20 | Roche Glycart Ag | Anticuerpos biespecificos agonistas de receptores de muerte. |
| EA201492253A1 (ru) | 2009-12-29 | 2015-06-30 | Эмерджент Продакт Дивелопмент Сиэтл, Ллс | Конструкторы, связывающиеся с ron, и способы их использования |
| US8318406B2 (en) | 2010-02-03 | 2012-11-27 | Eastman Kodak Company | Method for fixing a flexographic plate |
| TWI426920B (zh) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| JP5767207B2 (ja) | 2010-03-26 | 2015-08-19 | 協和発酵キリン株式会社 | 新規修飾部位導入抗体および抗体フラグメント |
| JP6022444B2 (ja) | 2010-05-14 | 2016-11-09 | ライナット ニューロサイエンス コーポレイション | ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法 |
| EP2606064B1 (en) | 2010-08-16 | 2015-02-25 | NovImmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| JP5758004B2 (ja) | 2010-08-24 | 2015-08-05 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体 |
| EP2609112B1 (en) | 2010-08-24 | 2017-11-22 | Roche Glycart AG | Activatable bispecific antibodies |
| EP2625200A1 (en) | 2010-10-05 | 2013-08-14 | F.Hoffmann-La Roche Ag | Antibodies against human tweak and uses thereof |
| WO2012058768A1 (en) | 2010-11-05 | 2012-05-10 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| AR084053A1 (es) | 2010-11-30 | 2013-04-17 | Chugai Pharmaceutical Co Ltd | Agente terapeutico que induce citotoxicidad |
| KR102099462B1 (ko) | 2010-11-30 | 2020-04-10 | 제넨테크, 인크. | 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도 |
| KR101572338B1 (ko) | 2011-02-28 | 2015-11-26 | 에프. 호프만-라 로슈 아게 | 1가 항원 결합 단백질 |
| KR101638224B1 (ko) | 2011-02-28 | 2016-07-08 | 에프. 호프만-라 로슈 아게 | 항원 결합 단백질 |
| WO2012131555A2 (en) | 2011-03-25 | 2012-10-04 | Glenmark Pharmaceuticals S.A. | Hetero-dimeric immunoglobulins |
| EP2699600A1 (en) | 2011-04-20 | 2014-02-26 | Roche Glycart AG | Method and constructs for the ph dependent passage of the blood-brain-barrier |
| CN102302039B (zh) | 2011-06-16 | 2014-01-29 | 北京泛博化学股份有限公司 | 双阳离子季铵盐络合碘消毒剂及其应用 |
| CN109517059B (zh) | 2011-06-30 | 2023-03-28 | 中外制药株式会社 | 异源二聚化多肽 |
| US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
| AU2012298537B2 (en) | 2011-08-23 | 2017-08-10 | Roche Glycart Ag | Bispecific T cell activating antigen binding molecules |
| US20130058937A1 (en) | 2011-08-23 | 2013-03-07 | Johannes Auer | Bispecific antigen binding molecules |
| CN103781801B (zh) | 2011-08-23 | 2018-02-09 | 罗切格利卡特公司 | 包含两个Fab片段的无Fc的抗体及使用方法 |
| KR101681818B1 (ko) | 2011-08-23 | 2016-12-01 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
| CN109111524B (zh) | 2011-10-31 | 2022-10-28 | 中外制药株式会社 | 控制了重链与轻链的缔合的抗原结合分子 |
| CA2859767C (en) | 2011-12-19 | 2018-09-11 | Synimmune Gmbh | Bispecific antibody molecule and use thereof for treatment of proliferative disease |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| BR112014024903A2 (pt) | 2012-04-05 | 2017-07-11 | Hoffmann La Roche | anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos |
| SG10201913376XA (en) | 2012-04-20 | 2020-02-27 | Merus Nv | Methods and means for the production of ig-like molecules |
| MX2014014162A (es) | 2012-05-24 | 2015-02-04 | Hoffmann La Roche | Anticuerpos multiespecificos. |
| EP3401337A1 (en) | 2012-09-25 | 2018-11-14 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| BR112015007120A2 (pt) | 2012-10-08 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| BR112015012385A2 (pt) | 2012-11-28 | 2019-08-27 | Zymeworks Inc | constructo de polipeptídeo de ligação de antígeno isolado, polinucleotídeo isolado ou conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do constructo, método para tratar um sujeito tendo uma doença ou distúrbio ou câncer ou doença vascular, método para inibir, reduzir ou bloquear um sinal dentro de uma célula, método para obter o constructo, método para preparar o constructo, meio de armazenamento legível por computador, método implementado por computador e método para produzir um constructo de polipeptídeo de ligação de antígeno bi-específico |
| US10766960B2 (en) | 2012-12-27 | 2020-09-08 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| EP3041862B1 (en) | 2013-09-05 | 2020-05-06 | IGM Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
| CN105612182B (zh) | 2013-10-11 | 2019-12-10 | 豪夫迈·罗氏有限公司 | 多特异性结构域交换共有可变轻链抗体 |
| CN112062853B (zh) | 2013-12-20 | 2024-01-09 | 豪夫迈·罗氏有限公司 | 双特异性her2抗体及使用方法 |
| WO2015101588A1 (en) | 2014-01-06 | 2015-07-09 | F. Hoffmann-La Roche Ag | Monovalent blood brain barrier shuttle modules |
| MX2016008540A (es) | 2014-01-15 | 2016-09-26 | Hoffmann La Roche | Variantes de region fc con propiedades de union al receptor fc neonatal (fcrn). |
| JP6786392B2 (ja) | 2014-01-15 | 2020-11-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ＦｃＲｎ結合特性が改変され、プロテインＡ結合特性が保持されているＦｃ領域変異体 |
| KR20160104636A (ko) | 2014-01-15 | 2016-09-05 | 에프. 호프만-라 로슈 아게 | 단백질 Ａ-결합이 개선된 Ｆｃ-영역 변이체 |
| UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| JP6744292B2 (ja) | 2014-07-29 | 2020-08-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 多重特異性抗体 |
| ES2979976T3 (es) | 2014-08-04 | 2024-09-27 | Hoffmann La Roche | Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| SG11201702805TA (en) | 2014-10-08 | 2017-05-30 | Hoffmann La Roche | Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents |
| US11952421B2 (en) | 2014-10-09 | 2024-04-09 | Bristol-Myers Squibb Company | Bispecific antibodies against CD3EPSILON and ROR1 |
| EA201791121A1 (ru) | 2014-11-20 | 2018-04-30 | Ф. Хоффманн-Ля Рош Аг | Активирующие т-клетки биспецифические антигенсвязывающие молекулы против folri и cd3 |
| KR20170087486A (ko) | 2014-11-20 | 2017-07-28 | 에프. 호프만-라 로슈 아게 | 일반 경쇄 및 이의 사용 방법 |
| CN108290958B (zh) | 2015-10-02 | 2021-12-28 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
| CN108026177B (zh) | 2015-10-02 | 2021-11-26 | 豪夫迈·罗氏有限公司 | 双特异性抗cd19xcd3 t细胞活化性抗原结合分子 |
| US20170096485A1 (en) | 2015-10-02 | 2017-04-06 | Hoffmann-La Roche Inc. | Bispecific t cell activating antigen binding molecules |
| EP3150636A1 (en) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
| CR20180161A (es) | 2015-10-02 | 2018-05-25 | Hoffmann La Roche | Anticuerpos biespecíficos para pd1 y tim3 |
| WO2017055393A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules |
| WO2017055392A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules |
| AR106201A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | Moléculas biespecíficas de unión a antígeno activadoras de células t |
| KR20180053674A (ko) | 2015-10-02 | 2018-05-23 | 에프. 호프만-라 로슈 아게 | 공자극 tnf 수용체에 특이적인 이중특이성 항체 |
| WO2017055318A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Cd33xcd3 bispecific t cell activating antigen binding molecules |
| WO2017055385A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xgd2 bispecific t cell activating antigen binding molecules |
| CN107949574A (zh) | 2015-10-02 | 2018-04-20 | 豪夫迈·罗氏有限公司 | 双特异性t细胞活化性抗原结合分子 |
| MX2018004157A (es) | 2015-10-07 | 2019-04-01 | F Hoffmann La Roche Ag | Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador. |
-
2008
- 2008-12-11 US US12/332,486 patent/US20090162359A1/en not_active Abandoned
- 2008-12-16 JP JP2010538441A patent/JP5281097B2/ja active Active
- 2008-12-16 RU RU2010129549/10A patent/RU2587616C2/ru active
- 2008-12-16 WO PCT/EP2008/010703 patent/WO2009080252A1/en active Application Filing
- 2008-12-16 MX MX2010006396A patent/MX2010006396A/es active IP Right Grant
- 2008-12-16 EP EP08864374.7A patent/EP2225279B1/en active Active
- 2008-12-16 KR KR1020107013760A patent/KR101249607B1/ko active IP Right Grant
- 2008-12-16 CA CA2709023A patent/CA2709023C/en active Active
- 2008-12-16 CN CN2008801219004A patent/CN101903404B/zh active Active
- 2008-12-16 AU AU2008340693A patent/AU2008340693A1/en not_active Abandoned
- 2008-12-16 NZ NZ585627A patent/NZ585627A/en not_active IP Right Cessation
- 2008-12-16 BR BRPI0821791-2A patent/BRPI0821791B1/pt active IP Right Grant
- 2008-12-16 ES ES08864374.7T patent/ES2469791T3/es active Active
- 2008-12-17 CL CL2008003781A patent/CL2008003781A1/es unknown
- 2008-12-17 TW TW097149168A patent/TWI359027B/zh not_active IP Right Cessation
- 2008-12-17 AR ARP080105485A patent/AR071547A1/es not_active Application Discontinuation
- 2008-12-17 PE PE2008002108A patent/PE20091172A1/es not_active Application Discontinuation
-
2010
- 2010-05-25 CR CR11460A patent/CR11460A/es not_active Application Discontinuation
- 2010-05-31 CO CO10065316A patent/CO6280542A2/es not_active Application Discontinuation
- 2010-06-03 IL IL206161A patent/IL206161A0/en unknown
- 2010-06-09 MA MA32899A patent/MA31904B1/fr unknown
- 2010-06-18 EC EC2010010270A patent/ECSP10010270A/es unknown
-
2012
- 2012-01-31 US US13/362,010 patent/US20120164726A1/en not_active Abandoned
- 2012-01-31 US US13/362,000 patent/US10138293B2/en active Active
-
2013
- 2013-08-30 US US14/015,952 patent/US20140120613A1/en not_active Abandoned
-
2018
- 2018-11-26 US US16/200,295 patent/US10927163B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010129549A (ru) | Двухвалентные биспецифические антитела | |
| RU2010129539A (ru) | Двухвалентные биспецифические антитела | |
| RU2012101485A (ru) | Биспецифические четырехвалентные антигенсвязывающие белки | |
| RU2014149681A (ru) | Антитела с множественной специфичностью | |
| RU2011153016A (ru) | Три- или тетраспецифические антитела | |
| RU2013141078A (ru) | Одновалентные антигенсвязывающие белки | |
| ES2547463T3 (es) | Moléculas de unión a ILT3 y usos de las mismas | |
| RU2012143798A (ru) | Биспецифические антитела | |
| ES2657443T3 (es) | Anticuerpos anti-GITR y usos de los mismos | |
| AR118118A2 (es) | Anticuerpos bivalentes biespecíficos | |
| HRP20191704T1 (hr) | Multispecifična protutijela | |
| RU2012130945A (ru) | Способ снижения иммуногенности | |
| HRP20191446T1 (hr) | Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula | |
| RU2013110875A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv | |
| RU2013110876A (ru) | Активируемые биспецифические антитела | |
| MX2007007484A (es) | Anticuerpos dirigidos a angiopoyetina 2 y usos de los mismos. | |
| RU2014104577A (ru) | Оптимизация растворимости иммуносвязывающих средств | |
| EA201390453A1 (ru) | Человеческие анти-тау антитела | |
| RU2010133547A (ru) | Анти-cldn антитела | |
| EA200800812A1 (ru) | Композиции антитела против cd3 | |
| UY30002A1 (es) | Proteínas de unión específicas de factores de crecimiento tipo insulina y usos de las mismas | |
| RU2011115845A (ru) | Антитело против глипикана 3 | |
| CO6280541A2 (es) | Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40 | |
| BRPI0613382A8 (pt) | anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor | |
| EA201490825A1 (ru) | Tdp-43-специфически связывающие молекулы |